$武田製藥(TAK.US)$Takeda Says Primary And Key Secondary Endpoints Were Met In Narcolepsy Type 1 Phase 2b Trial; The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001). Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...
The emergence of artificial intelligence (AI) in healthcare is transforming the medical industry by improving research, diagnoses, and treatment outcomes, and even drug discovery. Let's take a look at a few of the different types of artificial intelligence and healthcare industry benefits that can be derived from their use. The Competition to Discover the First Drug with AI Insilico Medicine, ...
武田製藥股票討論區
Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type
Update
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...
Results wen
FDA Results tomorrow. LFG
專欄Revolutionizing Healthcare: The Impressive Emergence of Artificial Intelligence in Medical Applications
Let's take a look at a few of the different types of artificial intelligence and healthcare industry benefits that can be derived from their use.
The Competition to Discover the First Drug with AI
Insilico Medicine, ...
專欄US Top Gap Ups and Downs on 9/12: ORCL, PKX, CASY, NBIX and More
Gap Ups
1. $Caseys General Stores(CASY.US)$ - up 4.9%
2.$神經分泌生物科學(NBIX.US)$ - up 3.4%
3. $基立福(GRFS.US)$ - up 2.4%
4. $Stellantis NV(STLA.US)$ - up 1.1%
5. $武田製藥(TAK.US)$ - up 1.1%
6. $諾華製藥(NVS.US)$ - up 0.8%
7. $沃達豐(VOD.US)$ - up 0.7%
8. $齊昂銀行(ZION.US)$ - up 0.6...
專欄US Top Gap Ups and Downs on 6/27: U, SAN, WBA, ARGX and More
Gap Ups
1. $韓國電力(KEP.US)$ - up 3.7%
2. $Unity Software(U.US)$ - up 2.9%
3. $網易(NTES.US)$ - up 1.7%
4. $桑坦德銀行(SAN.US)$ - up 1.5%
5. $家樂氏(K.US)$ - up 1.5%
6. $Saia(SAIA.US)$ - up 0.9%
7. $英國保誠(PUK.US)$ - up 0.9%
8. $羅技(LOGI.US)$ - up 0...
Watching this for long term potential loading at 15-16 range
2023年利息費用佔營業利潤的22%,利息負擔較重。
5年來資產負債率從62.4%下降到54.5%,應收賬款在下降,存貨有所上升,不過比例還算正常。
商譽達到4.79萬億,達到淨資產6.35萬億的75%。
長期借款4.04萬億,達到淨資產的64%,考慮到淨資產中商譽佔比,實際槓桿率很高。
5年來經營淨額略高於投資淨額,股東盈餘不多。
目前市盈率27.4,和營業利潤增速比有一定低估,但是負債表不是很好看,暫時觀望。
暫無評論